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Objectives The authors sought to study the characteristics and outcomes of patients with contralat-
eral carotid artery occlusions (CCOs) undergoing elective carotid artery stenting (CAS).
Background CCOs are associated with adverse neurological events following carotid endarterectomy.
Methods In-hospital outcomes were examined in patients with and without CCO undergoing elective
CAS in the Carotid Artery Revascularization and Endarterectomy (CARE) registry. A CCO was deﬁned as a
100% occlusion of the contralateral internal carotid artery. To minimize differences in measured comor-
bidities, a 3:1 propensity matching analysis was performed comparing 42 clinical and demographic vari-
ables between CCO and non-CCO patients from the CARE registry. The primary endpoint was a compos-
ite of in-hospital death, nonfatal myocardial infarction, and nonfatal stroke.
Results Between April 2005 and January 2012, 13,993 eligible patients underwent elective CAS, of
whom 1,450 (10%) had CCO. There were 5,500 CAS procedures (1,375 CCO and 4,125 non-CCO)
identiﬁed in the propensity analysis. The primary composite endpoint occurred in 29 (2.1%) and 107
(2.6%) patients with and without CCO, respectively (adjusted odds ratio: 0.81, 95% conﬁdence inter-
val: 0.53 to 1.23, p  0.316).
Conclusions In the CARE registry, there was no evidence that the presence of a CCO was associ-
ated with an increased risk of in-hospital death, nonfatal myocardial infarction, or nonfatal stroke in
patients undergoing elective CAS. These ﬁndings may have implications on the selection of carotid
revascularization procedures for such patients. (J Am Coll Cardiol Intv 2013;6:59–64) © 2013 by
the American College of Cardiology Foundation
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60Stroke is the fourth leading cause of death and was
associated with approximately $74 billion in economic costs
in 2010 (1). More than 80% of all strokes are ischemic in
origin (2). Although carotid endarterectomy (CEA) is
associated with greater long-term survival free of stroke than
medical therapy (3,4), patients with high-risk contralateral
carotid occlusions (CCOs), which occur in 6% to 10% of
patients undergoing CEA, are at much greater risk of
periprocedural death, nonfatal myocardial infarction, or
stroke (5). Emerging evidence from a high-risk patient
population suggests that elective carotid artery stenting
(CAS) is an acceptable treatment option for patients if
performed by an experienced operator in a thoughtfully
selected patient population (6). However, data quantifying
the prevalence and outcomes of elective CAS in patients
with a CCO have not been completely described. In this
study, we compared in-hospital outcomes between patients
with and without CCOs undergoing elective CAS in the
nationwide CARE (Carotid Artery Revascularization and
Endarterectomy) registry.
Methods
The CARE registry is a nation-
wide program for carotid revas-
cularization procedures operated
by the NCDR (National Car-
diovascular Data Registry) since
2005 to measure patient out-
comes and ensure quality im-
provement. A description of the
CARE registry has been previ-
ously published (7). Briefly, 186
centers in the United States vol-
untarily participate in collection
and validation of demographic, medical history, and proce-
dural data from patients undergoing either CAS or CEA.
Data are collected from existing medical records using
standardized definitions, collection protocols, and tools. An
on-site registry manager is designated by each participating
center to ensure data accuracy and timely submission to
NCDR.
Study population. For the purpose of this study, we iden-
tified patients with and without a CCO undergoing elective
CAS between April 2005 and January 2012. Patients were
stratified by the presence or absence of neurological symp-
toms related to the target lesion within the past 6 months,
by age 70 or 70 years, and by sex. There were 15,281
CAS procedures during this time. After excluding acute
evolving stroke (n  431), spontaneous dissection (n 
141), and general anesthesia (n  716), there were 13,993
CAS procedures in the analytical cohort (Fig. 1). Pre- and
Abbreviations
and Acronyms
CAS  carotid artery
stenting
CCO  contralateral carotid
occlusion
CEA  carotid
endarterectomy
CI  confidence interval
CVA  cerebrovascular
accident
IQR  interquartile range
OR  odds ratiopost-procedure National Institutes of Health Stroke Scale aassessment was performed in 9,927 (71.3%) and 9,193
(66.0%) patients, respectively, in the analytical cohort.
Deﬁnitions. CCO was defined as a 100% occluded con-
ralateral internal carotid artery. One patient was excluded
ue to an indicator for CCO missing from the database.
cute evolving stroke was defined as ongoing ischemia with
ymptoms at the time of the procedure, as well as each of the
ollowing: sudden development of neurological deficit at-
ributable to cerebral ischemia or infarction, onset of symp-
oms occurring within the prior 3 days of CAS, and
rogressively worsening symptomatology. Post-CAS ische-
ic stroke was defined as a focal neurological deficit in the
bsence of documented intracranial hemorrhage with resid-
al symptoms lasting 24 h and combined with impaired
unctional outcomes. Symptoms of ischemic stroke were
dentified as: 1) right hemispheric or retinal; 2) left hemi-
pheric or retinal; 3) vertebrobasilar; or 4) unknown.
Post-CAS myocardial infarction was identified by an
ncrease and decrease in cardiac biomarkers (preferably
roponin) with 1 value above the upper limit of normal,
Figure 1. Population Diagram
Number of patients with a contralateral carotid artery occlusion (CCO)
undergoing carotid artery stenting (CAS) analyzed before and after exclu-
sion criteria and after propensity matching.long with clinical evidence of myocardial ischemia consist-
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61ing of 1 of the following: 1) symptoms; 2) electrocardio-
graphic changes (new ST-T changes or left bundle branch
block); 3) development of pathological Q waves in the
electrocardiogram; or 4) new loss of viable myocardium or
new regional wall motion abnormality as evidenced by
imaging (8). Cardiac biomarkers were collected at the
discretion of each participating investigator following CAS.
Neurological symptom status in the target lesion was
determined in all patients before CAS. Symptomatic pa-
tients were not excluded in this analysis. Symptoms in-
cluded a prior history of carotid transient ischemic attack
with distinct focal neurological dysfunction persisting 24
h, nondisabling stroke with a modified Rankin scale3 and
ymptoms 24 h, or transient monocular blindness (amau-
osis fugax) within the previous 6 months.
An acute cerebrovascular accident (CVA) following CAS
as classified as sudden development of a neurological
eficit attributable to cerebral ischemia or infarction, symp-
om onset within 3 days before and ongoing at the time of
rocedure, or progressively worsening numbness or weak-
Table 1. Baseline Patient and Procedural Characteristics in Patients With
Unmatch
CCO
(n  1,450)
No CCO
(n  12,54
Demographics and risk factors
Age, yrs 68.9 9.9 71.1 10.3
Male 970 (66.9) 7,640 (60.9
Caucasian 1,327 (91.5) 11,547 (92.1
History of smoking 1,152 (79.4) 9,162 (73.0
Hypertension 1,326 (91.4) 11,362 (90.7
Dyslipidemia 1,268 (87.5) 10,953 (87.4
Diabetes 552 (38.1) 4,709 (37.6
Peripheral artery disease 682 (47.1) 5,355 (42.8
Ischemic heart disease 798 (55.2) 7,053 (56.3
MI within 6 weeks 48 (3.3) 311 (2.5)
History of heart failure 246 (17.0) 2,258 (18.0
NYHA class III/IV within 6 weeks 106 (7.3) 1,028 (8.2)
Neurological history
Transient ischemic attack 462 (31.9) 3,972 (31.7
Ischemic stroke 283 (19.5) 1,778 (14.2
Target lesion symptoms within 6 months 648 (44.8) 5,030 (40.2
CEA 346 (23.9) 2,841 (22.7
CAS 145 (10.0) 1,296 (10.3
CAS performed in a restenotic lesion
Either CAS or CEA 320 (22.07) 2,186 (17.4
CAS 83 (5.7) 358 (2.9)
CEA 259 (17.9) 1,953 (15.6
Procedural characteristics
Right vs. left carotid intervention 713 (49.2) 6,042 (48.2
EPD attempted 1,409 (97.3) 12,213 (97.5
Values are mean SD or n (%), and are before and after propensity matching.CAS carotid artery stenting; CCO contralateral carotid artery occlusion; CEA carotid endarterectomy; Eness, difficulty speaking or understanding, blurred or im-
paired vision, dizziness, or loss of balance and coordination.
The primary clinical endpoint was a composite of in-
hospital death, nonfatal myocardial infarction, or nonfatal
stroke. Secondary endpoints were the individual compo-
nents of the composite.
Statistical analysis. Data are presented as means with cor-
esponding 95% confidence intervals (CI), counts with
ercentages, or medians with interquartile ranges (IQR).
aseline characteristics of patients with and without CCO
ndergoing elective CAS were compared using standardized
ifferences. To address potential confounders in the primary
ndpoint, a propensity score was calculated and each patient
atched 3:1 (3 non-CCO to 1 CCO) on the basis of 42
linical and demographic variables using the nearest-
eighbor pair and a caliper width of 0.2 times the standard
eviation of the logit of the propensity score (9). Absolute
tandardized differences were computed to evaluate match-
ng effectiveness and are displayed in Table 1. Values 10%
nd closer to zero demonstrate a more balanced cohort (10).
thout a CCO
Propensity Matched
Standardized
Difference (%)
CCO
(n  1,375)
No CCO
(n  4,125)
Standardized
Difference (%)
21.8244 68.9 9.7 68.9 10.7 0.11341
12.4857 919 (66.8) 2,710 (65.7) 2.40948
1.9742 1,257 (91.4) 3,745 (90.8) 2.21353
15.0870 1,093 (79.5) 3,304 (80.1) 1.50903
2.7732 1,254 (91.2) 3,771 (91.4) 0.77433
0.3481 1,201 (87.3) 3,635 (88.1) 2.36431
1.1126 522 (38.0) 1,562 (37.9) 0.19982
8.8000 635 (46.2) 1,946 (47.2) 1.99189
2.1872 755 (54.9) 2,280 (55.3) 0.73090
4.9511 41 (3.0) 138 (3.3) 2.07719
2.6898 236 (17.2) 719 (17.4) 0.70489
3.3476 97 (7.1) 287 (7.0) 0.37981
0.4188 443 (32.2) 1,334 (32.3) 0.25919
14.3063 266 (19.3) 790 (19.2) 0.49180
9.3702 612 (44.5) 1,840 (44.6) 0.19505
2.8686 323 (23.5) 986 (23.9) 0.96896
1.0999 121 (8.8) 327 (7.9) 3.15205
11.68 292 (21.24) 878 (21.28) 0.1185
14.2281 72 (5.2) 194 (4.7) 2.45373
6.1736 238 (17.3) 753 (18.3) 2.47228
2.0648 679 (49.4) 1,897 (46.0) 6.86939
1.2732 1,338 (97.4) 4,015 (97.5) 0.60121or Wi
ed
3)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
3)
)
)
)PD embolic protection device; MImyocardial infarction; NYHANewYork Heart Association.
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62Odds ratios with 95% CI are reported for the primary and
secondary endpoints. The primary endpoint was also strat-
ified by asymptomatic and symptomatic patients, age 70
or 70 years, sex, and whether CAS was performed for de
novo or restenotic lesions. Sensitivity analyses were per-
formed using traditional univariate and multivariable mod-
eling on the entire cohort. A multivariable model was
constructed in the full analytical cohort, sequentially adjust-
ing for demographic and clinical characteristics, cardiovas-
cular risk factors, and lastly, prior neurological history. All
statistical analyses were performed using the SAS version
9.2 software (SAS Institute, Cary, North Carolina). A
2-sided p value 0.05 was considered statistically signifi-
cant.
Results
Between April 2005 and January 2012, 15,281 patients
underwent elective CAS at 180 participating CARE cen-
ters. After exclusions, there were 13,993 patients forming
the analytical cohort. The median (IQR) number of CAS
procedures by center was 45 (19 to 98). Of these patients,
1,450 (10%) had a CCO before the index procedure (IQR:
6.2% to 15.9% across centers).
Baseline, neurological, and procedural characteristics for
patients with and without a CCO are presented in Table 1,
both before and after matching. Before matching, patients
with CCO were younger, more frequently male, and more
likely to have a history of past or current smoking, recent
myocardial infarction, and neurological events before CAS.
Non-CCO patients were more likely to have undergone
previous CAS, whereas CCO patients were more likely to
have had a previous ischemic stroke, restenosis, or symp-
toms of a target lesion (Table 1). After propensity matching,
the standard differences or baseline covariables depicted in
Table 1 ranged from 0.11 to 6.9.
In-hospital events for the matched cohort as well as for
subgroups by age, symptom, and sex are shown in Table 2.
The primary composite endpoint occurred in 2.1% of CCO
patients and in 2.6% of non-CCO patients, p  0.316. The
in-hospital mortality rate is depicted in Table 2. Overall,
there were 28 deaths in the matched cohort: 16 were due to
neurological causes, 6 cardiac, 2 pulmonary, 1 vascular, 1
due to infection, and 2 were from other causes. One
post-CAS stroke was hemorrhagic, which occurred in a
CCO patient.
There were 1,170 CAS procedures performed on rest-
enotic lesions. Of these, 292 were among the CCO cohort
and 878 were among the non-CCO cohort. The primary
outcome occurred in 1.7% versus 2.1% of CCO versus
non-CCO patients, respectively, p  0.79. In 4,330 CAS
rocedures performed in de novo lesions, 1,083 were among
CO patients and 3,247 were among non-CCO patients.
he primary outcome occurred in 2.2% versus 2.7%, respec-ively, p  0.348. When stratified by symptom status, age,
r sex, the presence or absence of a CCO was not
ssociated with a difference in the primary endpoint
etween asymptomatic (p  0.120) or symptomatic (p 
.956) patients, in patients younger (p  0.426) or older
p  0.093) than 70 years, or in men (p  0.942) or
omen (p  0.093) (Table 2).
Results of sensitivity analyses using univariate and mul-
ivariable modeling for the entire cohort are shown in
igure 2. The unadjusted odds ratio (OR) of a CCO
redicting the primary outcome was 0.80 (95% CI: 0.55 to
.16, p  0.239). After adjustment for demographic and
ardiovascular risk factors, the OR was 0.91 (95% CI: 0.62
o 1.34, p  0.641). The addition of prior neurological
istory did not substantially alter the relationship (OR:
.88, 95% CI: 0.60 to 1.29, p  0.50). These results are
oncordant with outcomes relative to the propensity
atched cohort.
iscussion
In this nationwide registry of patients undergoing carotid
artery revascularization, the prevalence of CCOs in patients
undergoing elective carotid artery stenting was 10%. The
rate of composite in-hospital events, including death, non-
fatal myocardial infarction, and nonfatal stroke, did not
differ between patients with and without a CCO after
elective CAS. Lastly, CCO was not associated with higher
complications following CAS in older patients or individ-
Table 2. Primary Composite Endpoints Following CAS in the
Propensity-Matched Cohort
CCO
(n  1,375)
No CCO
(n  4,125) p Value
Composite events 29 (2.1) 107 (2.6) 0.316
Death 11 (0.8) 17 (0.4) 0.080
Nonfatal myocardial infarction 3 (0.2) 19 (0.5) 0.217
Nonfatal stroke 15 (1.1) 71 (1.7) 0.103
Asymptomatic patients (n 763) (n 2,285)
Composite events 8 (1.0) 43 (1.9) 0.120
Symptomatic patients (n 612) (n 1,840)
Composite events 21 (3.4) 64 (3.5) 0.956
Age 70 yrs (n 750) (n 2,198)
Composite events 8 (1.1) 32 (1.5) 0.426
Age 70 yrs (n 625) (n 1,927)
Composite events 21 (3.4) 75 (3.9%) 0.544
Male (n 919) (n 2,710)
Composite events 23 (2.5) 69 (2.5) 0.942
Female (n 456) (n 1,415)
Composite events 6 (1.3) 38 (2.7) 0.093
Values are n (% of group). Individual and composite rates of events are included for all CCO and
non-CCO patients and composite events by symptom status, age, and sex.
Abbreviations as in Table 1.uals with prior neurological symptoms.
OR 
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63The prognosis of medically treated patients with carotid
artery stenosis and a CCO is poor, with 2-year stroke rates
ranging from 40% to 70% (11,12). This excess risk is
believed to be related to inadequate collateral circulation at
the level of the circle of Willis (13), from compromised
ipsilateral blood supply in the setting of a complete CCO.
CCO is a well-recognized high-risk anatomic criterion for
patients undergoing CEA (5). Patients with CCO have
higher rates of perioperative stroke and death, as observed in
both the NASCET (North American Symptomatic Carotid
Endarterectomy Trial) (14) and ACAS (Asymptomatic Carotid
Atherosclerosis Study) (15) trials. In NASCET, the 30-day stroke
and death rate was 14.3% among patients with a CCO, although
more recent work suggests the rate is decreasing over time (5).
Although the mechanism for increased risk is not fully under-
stood, it is commonly believed to be related to a reduction in blood
flow during cross-clamping of the ipsilateral common carotid
artery during endarterectomy (16).
To our knowledge, the clinical efficacy and safety of CAS
in patients with carotid stenosis and a CCO has been
evaluated in only 7 previously published, retrospective stud-
ies (17–23), with a combined sample size of 500 patients
who underwent CAS in the setting of a CCO. As expected,
these studies varied widely in terms of design and sample
size, ranging from 18 (21) to 191 (23) patients. Other
Figure 2. Sensitivity Analysis Results
Odds of a contralateral carotid artery occlusion (CCO) to predict the primary o
factors, and prior neurological history, and in the propensity matched cohort.limitations of these studies included most being a single-center design (18,19,21,22), inconsistent use of distal pro-
tection devices on a routine basis between studies (21,23),
and few using a control group of patients without a CCO
(20,23). Nevertheless, event rates in these studies ranged
from 0% to 7.7% for death and 0% to 2.1% for major CVA,
both in agreement with results from the present analysis; and in
the largest study, in-hospital mortality and major CVA event
rates were 1.6% versus 1.4% for patients with and without a
CCO undergoing CAS, respectively (23). Our work also
represents the largest sample size to date assessing outcomes of
CCO patients undergoing CAS with the widespread applica-
tion of distal embolic protection devices, therefore reflecting
contemporary CAS practice in the United States.
Although we did not directly compare the outcomes of
CEA with CAS in patients with a CCO in the CARE
registry, CEA is known to be associated with increased risk in
the presence of CCO, whereas CAS appears to be safe in this
group of patients, potentially due to the widespread implemen-
tation of embolic protection devices during balloon inflation
and stent deployment. CAS appears to be a reasonable revas-
cularization option for patients with a contralateral carotid
occlusion if anatomically suitable for CAS.
Study limitations. Several important limitations associated
with our study should be noted. First, intermediate and
long-term follow-up for CARE patients is not available.
e before and after adjustment for clinical demographics, cardiovascular risk
odds ratio.utcomSecond, as a retrospective observational analysis, comparing
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64CCO with non-CCO, the presence of unmeasured confound-
ers is inherent. Finally, we did not compare outcomes of CAS
in the setting of a CCO with either medical therapy or CEA.
According to recent results from CARE (17), the characteris-
tics of patients referred for CAS differ markedly from those
referred for CEA, with more comorbidities in patients referred
for CAS, thus making comparisons of the 2 treatment strate-
gies from observational databases problematic. Nonetheless,
we believe that an indirect inference regarding the potential
advantages of CAS relative to other strategies in this group of
patients is warranted.
Conclusions
In this study, approximately 10% of CAS procedures were
performed in a setting of a CCO. There was no evidence that
the presence of a CCO was associated with an increased risk of
in-hospital death, nonfatal myocardial infarction, or nonfatal
stroke in patients undergoing elective CAS. These findings
may have implications on the selection of carotid revascular-
ization procedures for such patients.
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